Back to top

messenger-rna: Archive

Zacks Equity Research

Moderna (MRNA) Beats on Q2 Earnings, Starts $3B Buyback Program

Moderna's (MRNA) earnings and sales beat expectations. The company also announces another $3-billion buyback program. Stock gains in pre-market.

AZNPositive Net Change LLYPositive Net Change MRNAPositive Net Change JAZZPositive Net Change

Zacks Equity Research

Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?

Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the second-quarter earnings call that can lower its dependence on Spikevax.

AZNPositive Net Change MRNAPositive Net Change ADCTNegative Net Change IONSPositive Net Change

Zacks Equity Research

Pfizer (PFE), BioNTech Seek EU Nod for Omicron-Based COVID Jab

Pfizer (PFE) and BioNTech (BNTX) complete a regulatory filing for their Omicron-specific bivalent COVID-19 vaccine in the EU. The bivalent vaccine has been developed to target the Omicron BA.1 subvariant.

PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Moderna (MRNA) Starts Early-Stage Nipah Virus Vaccine Study

Moderna (MRNA) doses the first participant in the phase I study of its investigational mRNA vaccine, targeting the Nipah virus. It also starts a mid-stage study evaluating its Zika virus vaccine.

MRKPositive Net Change MRNAPositive Net Change SPPIPositive Net Change JAZZPositive Net Change

Zacks Equity Research

Moderna (MRNA) Bivalent COVID Booster Effective Against BA.4/5

Moderna's (MRNA) bivalent COVID booster candidate exhibits a higher antibody response against all-tested COVID-19 variants, including the Omicron subvariants BA.4 and BA.5.

PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change BNTXPositive Net Change

Zacks Equity Research

PFE, BNTX's COVID Jab Gets FDA's Full Nod for Adolescents

Pfizer (PFE) and partner BioNTech's (BNTX) Comirnaty is the first COVID-19 vaccine to receive full approval in the United States for use in adolescents aged 12 years and older.

PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change BNTXPositive Net Change

Sundeep Ganoria

FDA Recommends Adding New Omicron Subvariants to COVID Boosters

In anticipation of a new surge of COVID-19 infections later this year, the FDA recommends that COVID-19 vaccine manufacturers develop bivalent booster vaccines that contain the BA.4/BA.5 Omicron subvariants.

PFEPositive Net Change MRNAPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Pfizer (PFE) Inks Deal With US Government for COVID Jab Supply

Pfizer (PFE) and partner BioNTech (BNTX) enter into an agreement with the government of the United States to supply 105 million doses of its mRNA-based COVID-19 vaccine.

PFEPositive Net Change MRNAPositive Net Change SESNPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Pfizer's (PFE) Omicron-Based COVID Shot Betters Immune Response

Pfizer (PFE) and partner BioNTech's (BNTX) Omicron-specific COVID vaccine candidates achieves a higher immune response against the variant in a phase II/III study.

PFEPositive Net Change ALKSPositive Net Change MRNAPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Moderna (MRNA) Reveals New Data on Bivalent COVID Booster

Moderna's (MRNA) bivalent COVID booster candidate exhibits a greater than a 5-fold boost in antibody responses against the Omicron subvariants BA.4 and BA.5 in a phase II/III study.

PFEPositive Net Change ALKSPositive Net Change MRNAPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Sanofi (SNY), GSK COVID Booster Jab Effective Against Omicron

Data from clinical studies show that Sanofi (SNY) and Glaxo's (GSK) next-generation COVID-19 booster candidate elicits a stronger immune response in adults who received an mRNA vaccine as a primary regimen.

SNYPositive Net Change GSKPositive Net Change PFEPositive Net Change BNTXPositive Net Change